Bruker Management
Management criteria checks 4/4
Bruker's CEO is Frank Laukien, appointed in Feb 1991, has a tenure of 35.25 years. total yearly compensation is $4.71M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 26.54% of the company’s shares, worth $1.78B. The average tenure of the management team and the board of directors is 13.3 years and 10.3 years respectively.
Key information
Frank Laukien
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 20.75% |
| CEO tenure | 35.3yrs |
| CEO ownership | 26.5% |
| Management average tenure | 13.3yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Narrative Update • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Narrative Update • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
Narrative Update • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaNarrative Update • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Narrative Update • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Narrative Update • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Analysis Article • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Narrative Update • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Narrative Update • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Narrative Update • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Narrative Update • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Narrative Update • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Analysis Article • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Narrative Update • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Narrative Update • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Analysis Article • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Narrative Update • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Analysis Article • Jun 25
Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...Analysis Article • May 31
A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...Analysis Article • May 16
Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture
The market for Bruker Corporation's ( NASDAQ:BRKR ) shares didn't move much after it posted weak earnings recently. We...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$36m |
| Dec 31 2025 | US$5m | US$977k | -US$22m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | US$80m |
| Mar 31 2025 | n/a | n/a | US$80m |
| Dec 31 2024 | US$6m | US$966k | US$113m |
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
Compensation vs Market: Frank's total compensation ($USD4.71M) is below average for companies of similar size in the US market ($USD8.40M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Laukien (65 yo)
35.3yrs
Tenure
US$4,706,388
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation since February 1991. Dr. Laukien serves as the Chairman, Chief Executive Officer and Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 35.3yrs | US$4.71m | 26.54% $ 1.8b | |
| Executive VP & CFO | 8.2yrs | US$2.01m | 0.037% $ 2.5m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 13.7yrs | US$2.18m | 0.055% $ 3.7m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 13.3yrs | US$1.42m | 0.090% $ 6.1m | |
| President of Bruker BioSpin Group | 8yrs | US$1.42m | 0.020% $ 1.4m | |
| Chief Accounting Officer | 1.3yrs | no data | 0.00064% $ 43.0k | |
| Senior VP | no data | no data | no data | |
| President and CEO of Bruker Energy & Supercon Technologies | 18.1yrs | US$967.91k | 0.010% $ 705.2k |
13.3yrs
Average Tenure
60.5yo
Average Age
Experienced Management: BRKR's management team is seasoned and experienced (13.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 35.3yrs | US$4.71m | 26.54% $ 1.8b | |
| Independent Director | 10.8yrs | US$272.53k | 0.023% $ 1.6m | |
| Independent Director | 10.5yrs | US$260.20k | 0.023% $ 1.5m | |
| Lead Director | 19yrs | US$263.37k | 0.059% $ 3.9m | |
| Independent Director | 26.3yrs | US$252.95k | 0.039% $ 2.6m | |
| Independent Director | 1.3yrs | US$243.35k | no data | |
| Independent Director | 9yrs | US$252.03k | 0.016% $ 1.1m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 10.8yrs | US$247.62k | 0.017% $ 1.2m | |
| Independent Director | 5.7yrs | US$258.45k | 0.0088% $ 588.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 10yrs | US$247.62k | 0.012% $ 795.9k |
10.3yrs
Average Tenure
67yo
Average Age
Experienced Board: BRKR's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 15:41 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bruker Corporation is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |